Single Nucleotide Polymorphisms in CD36 Are Associated with Macular Pigment among Children.

Abstract

BACKGROUND\nHigh macular pigment optical density (MPOD) has been associated with improved eye health and better cognitive functions. Genetic variations have been associated with MPOD in adults. However, these associations between genetic variations and MPOD have not been studied in children.\n\n\nOBJECTIVES\nThis was a secondary analysis of the FK2 (Fitness Improves Thinking in Kids 2) trial (n\xa0=\xa0134, 41% male). The aim was to determine differences in MPOD among children (aged 7-9 y) based on genetic variants that either are biologically relevant to lutein (L) and zeaxanthin (Z) accumulation or have been associated with MPOD in adults.\n\n\nMETHODS\nMPOD was measured using customized heterochromatic flicker photometry via a macular densitometer. DXA was used to assess whole-body and visceral adiposity. DNA was extracted from saliva samples and was genotyped for 26 hypothesis-driven single nucleotide polymorphisms and 75 ancestry-informative markers (AIMs). Habitual diet history was obtained via 3-d food logs completed by parents (n\xa0=\xa088). General linear models were used to compare MPOD between different genotypes. Principal component analysis was performed for the AIMs to account for ethnic heterogeneity.\n\n\nRESULTS\nChildren carrying ≥1 minor allele on β-carotene-15,15 -monooxygenase (BCO1)-rs7501331 (T allele) (P\xa0=\xa00.045), cluster of differentiation 36(CD36)-rs1527483 (T allele) (P\xa0=\xa00.038), or CD36-rs3173798 (C allele) (P\xa0=\xa00.001) had significantly lower MPOD (range: 14.1%-26.4%) than those who were homozygotes for the major alleles. MPOD differences based on CD36-rs3173798 genotypes persisted after adjustment for dietary L and Z intake.\n\n\nCONCLUSIONS\nThe findings indicate that genetic variations of CD36 and BCO1 contribute to MPOD in children. The influence of genetic variation in CD36-rs3173798 persisted after adjusting for variation in dietary intake.This trial was registered at clinicaltrials.gov as NCT01619826.